-

ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Tuesday, November 14, 2023

LOS ANGELES--(BUSINESS WIRE)--ChromaDex Corporation (NASDAQ: CDXC), a global authority on Nicotinamide Adenine Dinucleotide (NAD+) and healthy aging research, announced today that they will be participating in Renmark Financial Communications Inc.’s live Virtual Non-Deal Roadshow Series to discuss its latest investor presentation on Tuesday, November 14, 2023, at 2:00 PM EDT. ChromaDex welcomes stakeholders, investors, and other individual followers to register and attend these live events.

ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Tuesday, November 14, 2023

Share

The presentations will feature Rob Fried, Chief Executive Officer, and Brianna Gerber, Chief Financial Officer. Topics to be covered will include the latest investor presentation followed by a live Q&A. Investors interested in participating in either of these events will need to register using the links below. As a reminder, registration for the live events may be limited but access to the replay after the events will be on the investor section of the Company’s website.

REGISTER HERE:

Tuesday, November 14, 2023: https://www.renmarkfinancial.com/live-registration/renmark-virtual-non-deal-roadshow-nasdaq-cdxc-2023-11-14-130000

  • To ensure smooth connectivity, please access this link using the latest version of Google Chrome.

About ChromaDex Corporation

ChromaDex Corp. is a global bioscience company dedicated to healthy aging. The ChromaDex team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. ChromaDex is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen®. Nicotinamide riboside and other NAD+ precursors are protected by ChromaDex’s patent portfolio. ChromaDex maintains a website at www.chromadex.com to which ChromaDex regularly posts copies of its press releases as well as additional and financial information about the Company.

About Renmark Financial Communications Inc.

Founded in 1999, Renmark Financial Communications Inc. is North America’s leading retail investor relations firm. Employing a strategic and comprehensive mix of exposure tactics; Renmark hosts Virtual Non-Deal Roadshows as well as in-person corporate presentations and maintains daily communications with thousands of brokers and money managers across Canada and the United States. Renmark empowers its publicly-traded clientele to maximize their visibility within the financial community and strengthen their investor audience.

Contacts

Renmark Financial Communications Inc.
James R. Kautz: jkautz@renmarkfinancial.com
Tel.: (416) 644-2020 or (212) 812-7680
www.renmarkfinancial.com

Industry:

ChromaDex Corporation

NASDAQ:CDXC
Release Versions
English
$Cashtags
$CDXC
Hashtags
#ChromaDex
#IR
#InvestorRoadShow

Contacts

Renmark Financial Communications Inc.
James R. Kautz: jkautz@renmarkfinancial.com
Tel.: (416) 644-2020 or (212) 812-7680
www.renmarkfinancial.com

Social Media Profiles
ChromaDex Facebook
ChromaDex LinkedIn
ChromaDex Twitter
More News From ChromaDex Corporation

Niagen Bioscience is the Premiere Sponsor of the Inaugural “NAD for Health: Opportunities & Challenges” Conference Hosted by the University of Copenhagen

LOS ANGELES--(BUSINESS WIRE)--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces it is the headlining sponsor of the inaugural NAD for Health: Opportunities & Challenges scientific meeting hosted by the University of Copenhagen, taking place March 23–25, 2026 at the Royal Danish Academy of Sciences and Letters in central Copenhagen. Space is limited and registration is require...

Niagen Bioscience to Report Fourth Quarter and Full Year 2025 Financial Results on Wednesday, March 4, 2026

LOS ANGELES--(BUSINESS WIRE)--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, announces that it will hold a conference call on Wednesday, March 4, 2026, at 4:30 p.m. ET to discuss its financial results for the fourth quarter and fiscal year 2025, which ended December 31, 2025. The financial results will be reported in a press release after the close of regular stock market trading hours on Wed...

Niagen Bioscience Expands HSA/FSA Access for Tru Niagen®, the Leading NAD+ Supplement in the U.S.*

LOS ANGELES--(BUSINESS WIRE)--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that it has partnered with Truemed to provide qualified customers the option to purchase Tru Niagen®, the number one NAD+ supplement in the United States*, using Health Savings Account (HSA) and Flexible Spending Account (FSA) funds on its direct-to-consumer website, www.truniagen.com. Qualified custo...
Back to Newsroom